Video Journal of Hematology & Hematological Oncology (VJHemOnc)

Introducing: VJ in Practice 🧫 🔬🩸 We're excited to share some exclusive INTERACTIVE #hemepath #casestudies with you! 🔦 Learn more about: 🩸 Approaching diagnosis and #diseaseclassification 🩸 Treatment options for newly diagnosed #AML 🩸 The importance of recurrent #geneticalterations when making #treatment decisions With expert insight from Sanam Loghavi and Naval Daver (MD Anderson Cancer Center) 🔦 Up for the challenge? Get started 👉 https://ow.ly/GbrX50R88X5 Big thank you to Sanam Loghavi for working on these with us! 🧡 #VJHemOnc #Hematologycasestudy #Leusm #AMLsm #AMLCaseStudy #InteractiveCaseStudy #HealthcareInnovation #MedicalEducation

Insights from The MPN Workshop of the Carolinas 2024 🩺🔬 From August 23-25, The MPN Workshop of the Carolinas brought together clinicians and researchers to discuss the latest in myeloproliferative neoplasms (MPN). The workshop focused on advancing understanding of effective therapies, evaluating molecular responses as clinical outcome markers, and exploring treatment improvements by targeting MPN stem cells and the hematopoietic stem cell niche. Ruben Mesa, MD Atrium Health Naveen Pemmaraju, MD MD Anderson Cancer Center Jyoti Nangalia Stephen Oh Washington University School of Medicine in St. Louis Video Journal of Hematology & Hematological Oncology (VJHemOnc) Jeanne Palmer Mayo Clinic The conference provided valuable insights aimed at enhancing MPN management and patient outcomes 👇 https://lnkd.in/eTqK-rkp #Cancer #WorkshopNC24 #OncoDaily #Oncology #MPNWorkshop2024 #MedicalResearch

NEW #podcast episode: '#Hemophilia updates from #ISTH2024: ongoing #clinicaltrials, emerging #gene therapies & remaining challenges' 🎧🩸 This week’s VJHemOnc podcast brings you updates in #hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually Leading experts discuss key #hemophilia clinical trials in 2024, #genetherapies for #hemophilia & remaining challenges for patients with #hemophilia 🧬 💡 With: 🌟 Omolade Awodu, MBChB, MD, FMCPath, University of Benin 🌟 Radoslaw (Radek) Kaczmarek, PhD, Indiana University School of Medicine 🌟 Matteo Luciani, MD, Bambino Gesù Children’s Hospital Give it a listen 👉 https://lnkd.in/emfue-Z4 #VJHemOnc #Hematologynews

Spotlight On Cardio-Oncology 🗞️ 🔎🩸 Alongside the development of an ever-increasing number of #cancer therapies available for patients, cancer survivorship has steadily increased over the past three decades, and the impact on patients has been significant 📈 However, with new therapies, comes new challenges, and the management of cancer therapy-related #cardiovasculartoxicity (CTR-CVT) has become an important consideration for #healthcare professionals 🔦 🫀 Learn about managing #cardiovascular-related #toxicities in #hematologicalmalignancies Covering: #CLL, #lymphoma, #amyloidosis, #AML, #MDS & #Leukemia Take a look 👉 https://lnkd.in/enkb2673 #VJHemOnc

🌟 Naveen Pemmaraju, MD and Ruben Mesa, MD have kicked off the inaugural MPN Workshop of The Carolinas (MPNWorkshopNC24) in Asheville, NC! 🌟 As co-chairs, they are leading this important international gathering of experts in Myeloproliferative Neoplasms. The workshop promises impactful discussions and valuable collaborations in the field. https://lnkd.in/euk4Smi2 #MPNWorkshopNC24 #Oncology #HealthCare #Cancer #OncoDaily

👉👉👉Wonderful to kick-off today with my dear friend & colleague Ruben Mesa, MD our exciting inaugural meeting together as Co-Chairs 🙌 of The MPN Workshop of The Carolinas #MPNWorkshopNC24 in #Asheville NC this week! An important international gathering of scientists, researchers, physicians, and all stakeholders across the world interested in our Myeloproliferative Neoplasm field. #MPNSM Video Journal of Hematology & Hematological Oncology (VJHemOnc) MPN Advocacy

We are thrilled to bring you a NEW CME accredited feature on 'Practical Considerations for CAR-T Therapy in #Hematological Malignancies' 🗞️ 🔦 Hear from leaders in the field on how to identify, refer, and monitor patients with #multiplemyeloma, #lymphoma, or #acutelymphoblasticleukemia (#ALL) who receive #CARTtherapy 🩺🩸🔦 We cover: 💡 Practicalities Of CAR-T Therapy For Patients With Multiple #Myeloma 💡 Practicalities Of CAR-T Therapy For Patients With #Lymphoma 💡 Practicalities Of CAR-T Therapy For Patients With #ALL 💡 Understanding The CAR-T Therapy Process 💡 Current Status Of CAR-T Therapy For #Pediatric And AYA Patients 💡 Measuring And Managing #Toxicities Following CAR-T Therapy Explore the feature 👉 https://lnkd.in/eBX9gZHb Earn 1.5 CME credits ✅ Partners for Advancing Clinical Education (PACE) accreditation information can be found on this linked page 👉 https://lnkd.in/eBX9gZHb #HemOnc #Hematologynews #CMEaccredited #Leusm #Lymsm #MMsm

Spotlight on: Prolonging #Remission In Patients With #AML 🗞️🩸 Learn more about: 🌟 Novel #transplant strategies, and reducing the risk of #relapse, Charlie Craddock 🌟 #VENTOGRAFT trial: AZA, VEN, and DLI in patients with #MDS and #AML who have relapsed following #alloSCT, Thomas Cluzeau 🌟 #Gilteritinib as post-#transplant maintenance therapy in #FLT3-ITD #AML, Mark Levis 🌟 Approaching patients with #MDS and #AML who relapse after #alloSCT & strategies to prevent #relapse, Pramila K. Take a look 👉 https://lnkd.in/eNm-pa2h #VJHemOnc #Leusm

NEW #podcast episode: 'Inflammation and #immune interventions in #MDS: targeting STAT, #IRAK4, & more' 🎧🩸 In #myelodysplasticsyndromes (#MDS), #chronicinflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant #hematopoiesis and the promotion of a pro-#inflammatory environment that supports the clonal expansion of #malignant cells 💡 During this episode, #MDS experts discuss the role of #inflammation and #immune interventions from the 2nd International Workshop on Myelodysplastic Syndromes and Myeloproliferative Neoplasms (iwMDS) 2024, held in Boston, MA 🇺🇸 They focus on the targeting of STAT and IRAK4, the pivotal Phase III STIMULUS-MDS2 trial (NCT04266301) of #sabatolimab, and lessons that can be learned from #clinicaltrial failures With: 🌟 Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University 🌟 Aditi Shastri, MD, MONTEFIORE MEDICAL CENTER 🌟 Uwe Platzbecker, MD, Leipzig University 🌟 Amer Zeidan, MBBS, Yale University and Yale Cancer Center Give it a listen 👉 https://lnkd.in/eFD4YfVX #VJHemOnc #Hematologynews #MDSsm

Spotlight on Lower-risk #MDS 🗞️🩸 The first in a practical #educational series 🔎💡🎥 Learn more about: ⭐ Updates on #risk-stratification & #disease #classification ⭐ Recognizing #ESAfailure, and when to switch therapy ⭐ The latest #therapy updates for LR-#MDS beyond #ESAs And hear from leading #MDS experts: Uwe Platzbecker, MD (Leipzig University), Sanam Loghavi, MD (MD Anderson Cancer Center), Rami Komrokji, (Moffitt Cancer Center), Robert Hasserjian, MD (Massachusetts General Hospital), Valeria Santini, MD, (Università degli Studi di Firenze) & many more Coming soon on this feature: ✅ Latest trial updates around sequencing and therapy combinations ✅ Dosing considerations and managing adverse events ✅ Patient case studies Take a look 👉 https://lnkd.in/dqF2SfPC #HemOnc #MDSsm #LRMDS